Most importantly, although anti-inflammatory interventions—for instance, infliximab—have shown promise in inflammatory subtypes of depression (e.g., patients with elevated CRP), prospective interventional trials targeting populations with depression–cancer comorbidity are conspicuously absent. This evidence concerns the gene CRP and cancer.